Global Pleural Effusion Treatment Market Report and Forecast 2025-2034

Key Trends in the Market

Pleural effusion, also known as ‘water on the lungs’ is an abnormal lung condition in which excess fluid builds up outside the lungs between the layers of pleura. They are usually caused by conditions such as pulmonary embolisms, congestive heart failure, pneumonia, and cancer. Some of the common pleural effusion treatments include pleurodesis, drainage catheter placement, surgery, and therapeutic thoracentesis. 

• Occurrences of pleural effusion are rapidly increasing because of growing prevalence of lung tumours, further fuelled by cigarette smoking. Other conditions such as blood vessel blockage, lung injuries, and congestive heart failures are also increasing the cases for pleural effusion increasing the demand for pleural effusion treatment.

• Major market players are carrying out research and development activities, launching new products to treat pleural effusions more easily and effectively.

• Increased awareness regarding pleural effusion and its symptoms is encouraging patients to seek out treatment earlier, supplementing the demand for the pleural effusion treatment market.

Market Segmentation

Market Share by Disease Type

Transudative effusion disease type has accounted for a large share in the pleural effusion treatment market because of the increasing prevalence of congestive heart failures, cirrhosis, and kidney failure that can lead to transudative effusion. Transudative is caused by a hydrostatic imbalance with a build-up of watery fluid outside the lungs. Increasing prevalence of such conditions are likely to result in an increase in transudative effusion cases. 

Exudate effusions are caused by increased capillary permeability that leads to leakage of cell, protein, and other serum constituent. Conditions that cause exudative effusion are tuberculosis, pneumonia, or diseases causing pleuro-renal syndromes. Demand for pleural effusion treatment for exudate effusions tends to vary depending upon region, and the prevalence of causing conditions. 

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Market Share by Region

North America accounted for a large share in the pleural effusion treatment market because of rising prevalence of the pleural effusion and rising cases of heart related diseases in the North American region. Furthermore, rising healthcare expenditure, increase in geriatric populations, and robust healthcare infrastructure in countries such as the United States have supported the growth of the region in the overall market. 

Asia Pacific is also expected to observe a significant growth in the market for pleural effusion treatment owing to increasing cases of respiratory disorder and lung cancer. With advancements in healthcare technology used in the region, multiple treatment options for pleural effusion are becoming increasingly accessible in the Asia Pacific.

Competitive Landscape

Other market players include B. Braun Melsungen AG, and Becton, Dickinson, and Company, among others.